RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer

Area of Science:

• Oncology
• Immunology
• Molecular Biology

Background:

• Pancreatic ductal adenocarcinoma (PDA) exhibits immune tolerance and resistance to immunotherapy.
• Tumor-associated macrophages (TAMs) play a crucial role in the tumor microenvironment of PDA.
• Receptor-interacting serine/threonine protein kinase 1 (RIP1) is upregulated in TAMs within PDA.

Purpose of the Study:

• To investigate the role of RIP1 in PDA oncogenic progression.
• To develop and utilize a selective small-molecule RIP1 inhibitor.
• To explore RIP1 inhibition's impact on TAM phenotype and anti-tumor immunity.

Main Methods:

• Development of a selective small-molecule RIP1 inhibitor.
• Analysis of TAM reprogramming in response to RIP1 inhibition.
• Assessment of cytotoxic T cell activation and T helper cell differentiation.
• Evaluation of RIP1 inhibition in mouse models and organotypic human PDA models.
• Testing of RIP1 inhibition in combination with PD1 and inducible co-stimulator immunotherapies.

Main Results:

• RIP1 inhibition reprogrammed TAMs to an MHCII^hiTNFα⁺IFNγ⁺ immunogenic phenotype via a STAT1-dependent pathway.
• Targeting RIP1 activated cytotoxic T cells and promoted T helper cell differentiation (Th1/Th17).
• RIP1 inhibition induced tumor immunity in preclinical PDA models.
• Combined RIP1 inhibition with PD1 and inducible co-stimulator immunotherapies showed synergistic effects.
• RIP1's tumor-promoting functions were independent of its association with RIP3.

Conclusions:

• RIP1 acts as a critical checkpoint kinase regulating tumor immunity in PDA.
• Targeting RIP1 in TAMs represents a promising strategy to overcome immune evasion in pancreatic cancer.
• RIP1 inhibition can enhance the efficacy of current immunotherapeutic approaches for PDA.